ThomasOrtelMD

Hematology • Durham, NC

Professor of Medicine, Duke University

Join to view full profile

Dr. Ortel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ortel's full profile

Already have an account?

Office
Duke Medical Ctr
Durham, NC 27710
Phone+1 919-620-4467

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1988 - 1991
Duke University HospitalResidency, Internal Medicine, 1985 - 1988
Indiana University School of MedicineClass of 1985

Certifications & Licensure

NC State Medical License 1989 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
Top MD Consumers Checkbook
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Optimal Platelet Dose Strategy for Management of Thrombocytopenia Start of enrollment: 2004 Jul 01
Completed
Phase 3
Fresh-Frozen Plasma Infusions to Reduce Risk of Bleeding Related to Invasive Procedures Start of enrollment: 2006 Mar 01
Withdrawn
Phase 3
Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery Start of enrollment: 2006 Jun 01
Completed
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome Start of enrollment: 2006 Jun 01
Recruiting
Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction Start of enrollment: 2007 Aug 01
Withdrawn
Not Applicable
Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study) Start of enrollment: 2008 Jan 01
Terminated
Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study) Start of enrollment: 2009 Jul 01
Completed
Phase 3
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) Start of enrollment: 2009 Apr 01
Terminated
Phase 3
Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism Start of enrollment: 2008 Nov 01
Completed
Phase 4
Red Cell Storage Duration Study Start of enrollment: 2010 Jan 01
Completed
Phase 3
Initial Treatment of Patients With Immune Thrombocytopenic Purpura Start of enrollment: 2010 Jan 01
Terminated
Phase 3
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction" Start of enrollment: 2010 May 01
Completed
Phase 1
Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study Start of enrollment: 2010 Jun 01
Completed
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) Start of enrollment: 2017 Oct 13
Completed
Phase 3
Roles: Principal Investigator
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura Start of enrollment: 2021 Apr 14
Recruiting
Phase 3
Roles: Principal Investigator
A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Start of enrollment: 2023 Mar 21
Recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

65 citations
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: A cross sectional study
John A. Heit, Michele G. Beckman, Paula L. Bockenstedt, Althea M. Grant, Nigel S. Key
American Journal of Hematology. 2010-07-01
124 citations
Single-chain structure of human ceruloplasmin: the complete amino acid sequence of the whole molecule
Nobuhiro Takahashi, Thomas L. Ortel, Frank W. Putnam
Proceedings of the National Academy of Sciences of the United States of America. 1984-01-01
94 citations
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial
Alok A. Khorana, Charles W. Francis, Nicole M. Kuderer, Marc Carrier, Thomas L. Ortel
Thrombosis Research. 2017-03-01

Journal Articles

Automated Versus Manual Data Extraction of the Padua Prediction Score for Venous Thromboembolism Risk in Hospitalized Older Adults
David Gallagher, Juliessa M Pavon, Harvey J Cohen, Thomas L Ortel, Applied Clinical Informatics

Abstracts/Posters

Risk Factors Associated with 6-Month Recurrent VTE Among Patients in Two Large Population-Based Surveillance Systems
Thomas L. Ortel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cancer- Associated Venous Thromboembolism (VTE) Characteristics in Blacks Compared to Whites in Durham County, North Carolina
Thomas L. Ortel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Hemostasis and Thrombosis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Laboratory Criteria for Antiphospholipid Syndrome: Reply
American Society of Hematology (ASH), Hollywood, California - 10/12/2012

Other

Laboratory Criteria for Antiphospholipid Syndrome: Reply
Thomas Ortel, MD, Journal of Thrombosis and Haemostasis
https://www.doximity.com/articles/9d2ed495-af3c-4907-8efa-27b82eedb4cc
UpToDate, Wolters Kluwer Health - 2012-03-19

Press Mentions

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU PatientsOctober 12th, 2021
Tackle the Triglycerides to Reduce ASCVD Risk, ACC SaysJuly 28th, 2021
Drug Problems: Hematologic Complications of Illicit Drug UseNovember 15th, 2019
Join now to see all